Diff Profiles › MTBLS5005_0002_00000001

Control_Liver_vs_Treatment_Liver

Control_Liver vs Treatment_Liver

p-value ≤ 0.05 16 significant 2025-09-26 00:00:00 Study: MTBLS5005
16 Total Features
16 Significant
0.05 p-value Threshold

Profile details

Identifier
MTBLS5005_0002_00000001
Linked study
MTBLS5005 — DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates
Comparison
Control_Liver vs Treatment_Liver
Group A
Control group for liver samples treated with H20 (vehicle).. Provides baseline data for liver tissue to compare against treatment effects.
Group B
Treatment group for liver samples treated with DT-109 (compound).. Evaluates the effect of DT-109 on liver tissue, providing insights into its therapeutic potential.
Total features tested
16
Significant features
16
p-value threshold
0.05
Ratio threshold (upper)
1.5
Ratio threshold (lower)
1/1.5
Date created
2025-09-26 00:00:00

Top hits

Metabolite ID (InChI Key) Name Direction Ratio p-value
ALWGEKGYDBQVFJ-DYFSFZQGSA-N [(2R)-1-pentadecanoyloxy-3-phosphonooxypropan-2-yl] (Z)-docos-13-enoate down 0.06428 0.0258
WKZHECFHXLTOLJ-QYKFWSDSSA-N C24:1 Sphingomyelin up 5.462 0.00631
SRQSAJRUMDQMMS-NLDJLLEISA-N PC(14:0/20:4) down 0.1568 0.0141
TWSHGCHPGCBTFY-UHFFFAOYSA-N 3,4,5-trihydroxy-6-[1-(4-methoxyphenyl)-3-oxopentoxy]oxane-2-carboxylic acid up 5.949 0.023
AKOSXIFOBUWPLU-UHFFFAOYSA-N 8-[6-hydroxy-5-(3-methylbut-2-enyl)-1-benzouran-2-yl]-2,2-dimethylchromen-5-ol up 4.011 0.0152
GOTYRUGSSMKFNF-UHFFFAOYSA-N 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline down 0.3176 0.00731
OKNSFVSKHQJVRN-XAYCFROHSA-N 20beta-Cortolone-3-glucuronide up 3.739 0.0195
AFPJDDPSVYDRDB-DRONAGRDSA-N (11<i>R</i>)-11-[3,6-dideoxy-4-<em>O</em>-(1<em>H</em>-indol-3-ylcarbonyl)-α-<small>L</small>-<i>arabino</i>-hexopyranosyloxy]lauric acid up 4.843 0.048
NWXXKKDLGZLEGH-UHFFFAOYSA-N 4-methyl-2-propan-2-yl-1,3-dioxolane down 0.4848 0.00174
RTEVGQJRTFFMLL-UHFFFAOYSA-N U 28288D down 0.2839 0.0287